Perspective Therapeutics, Inc.

Equities

CATX

US46489V1044

Medical Equipment, Supplies & Distribution

Market Closed - Nyse Other stock markets 16:00:00 2024-05-22 EDT			5-day change	1st Jan Change
1.49 ^USD	-6.29%		-5.10%	+270.65%

05-15	Transcript : Perspective Therapeutics, Inc. Presents at Bank of America Health Care Conference 2024, May-15-2024 10:00 AM
05-15	Perspective Therapeutics Swings to Loss in Q1, Revenue Rises	MT

Isoray, Inc. Appoints Lisa Lauer as Vice President Business Development

February 16, 2021 at 08:13 am

Isoray, Inc. announced that Lisa Lauer has been appointed Vice President, Business Development. Lisa Lauer brings more than 27 years of valuable expertise across a broad range of therapeutic markets and a proven track record in commercial execution, market access, reimbursement, and strategic portfolio development and management. Lauer joins Isoray following eleven years with Olympus Corporation.

Latest news about Perspective Therapeutics, Inc.

Transcript : Perspective Therapeutics, Inc. Presents at Bank of America Health Care Conference 2024, May-15-2024 10:00 AM	05-15
Perspective Therapeutics Swings to Loss in Q1, Revenue Rises	05-15	MT
Perspective Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-15	CI
RBC Starts Perspective Therapeutics With Outperform Rating, $3 Price Target	05-14	MT
Cantor Fitzgerald Starts Perspective Therapeutics With Overweight Rating	05-09	MT
Perspective Therapeutics, Inc. Announces the Selection of Investigational Product VMT-a-NET for the Treatment of Certain Patients with Neuroendocrine Tumors by the U.S. Food and Drug Administration to Participate in the Chemistry	04-30	CI
Certain Common Stock of Perspective Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 18-APR-2024.	04-17	CI
Certain Warrants of Perspective Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 18-APR-2024.	04-17	CI
Certain Stock Options of Perspective Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 18-APR-2024.	04-17	CI
B. Riley Raises Price Target on Perspective Therapeutics to $1.70 From $1.20, Maintains Buy Rating	04-09	MT
Oppenheimer Adjusts Perspective Therapeutics Price Target to $1.50 From $1.20, Maintains Outperform Rating	04-01	MT
Perspective Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-28	CI
North American Morning Briefing : Markets Steady -2-	03-26	DJ
North American Morning Briefing : Stock Futures -2-	03-19	DJ
Perspective Therapeutics, Bristol-Myers Squibb Collaborate on Melanoma Combination Study	03-18	MT
Transcript : Perspective Therapeutics, Inc. - Analyst/Investor Day	03-18
Perspective Therapeutics, Inc. Announces Clinical Collaboration Agreement with Bristol Myers Squibb to Evaluate [(212)Pb)VMT01 in Combination with Nivolumab in MC1R-Positive Metastatic Melanoma	03-18	CI
Perspective Therapeutics, Inc. announced that it has received $87.409482 million in funding from Lantheus Holdings, Inc. and other investors	03-05	CI
Sector Update: Health Care Stocks Softer in Afternoon Trading	03-04	MT
Perspective Therapeutics to Raise $87.4 Million in Private Placement	03-04	MT
Perspective Therapeutics, Inc. completed the acquisition of Radiopharmaceutical Manufacturing Facility in Somerset, New Jersey from Progenics Pharmaceuticals, Inc.	02-29	CI
Perspective Therapeutics, Inc. Introduces Pre-Targeting Theranostic Technology Platform	02-01	CI
B. Riley Starts Perspective Therapeutics With Buy Rating, $1.20 Price Target; Says Well-Positioned to Break Out of Biotech Pack	01-26	MT
Perspective Therapeutics Closes $89.8 Million Public Offering, Concurrent Private Placement	01-22	MT
Perspective Therapeutics to Raise Nearly $81 Million via Public Offering, Private Placement	01-18	MT

Chart Perspective Therapeutics, Inc.

Duration

Period

More charts

Company Profile

Perspective Therapeutics, Inc. is a radiopharmaceutical development company that is developing advanced treatment applications for cancers throughout the body. The Company has proprietary technology that utilizes the alpha-emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting peptides. It is also developing imaging diagnostics that incorporate the same targeting peptides, which provide the opportunity to personalize treatment and optimize patient outcomes. This theranostic approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity. The Company's melanoma (VMT01) and neuroendocrine tumor (VMT-Î±-NET) programs have entered Phase I/IIa imaging and therapy trials for the treatment of metastatic melanoma and neuroendocrine tumors at several academic institutions. It has also developed a 212Pb generator to secure key isotopes for clinical trial and commercial operations.

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-05-31 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for Perspective Therapeutics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.49 USD

Average target price

2.26 USD

Spread / Average Target

+51.68%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.
PERSPECTIVE THERAPEUTICS, INC.	+270.65%	933M
ABBOTT LABORATORIES	-4.77%	179B
MEDTRONIC PLC	+4.10%	113B
BECTON, DICKINSON AND COMPANY	-3.85%	67.88B
DEXCOM, INC.	+5.19%	52.03B
CENCORA, INC.	+5.54%	43.3B
HOYA CORPORATION	+6.13%	41.79B
METTLER-TOLEDO INTERNATIONAL, INC.	+23.81%	32.49B
TERUMO CORPORATION	+16.16%	25.65B
WEST PHARMACEUTICAL SERVICES, INC.	-5.06%	24.55B

Other Medical Equipment, Supplies & Distribution